Oragenics Inc (OGEN) Stock Price, Quote & News

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 286 7900

Website: www.oragenics.com

Address:

9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States

NMax Jul. 4 at 4:28 AM

$OGEN lol... So anyways... continuing to accumulate!!! 🤑🤑🤑

0 · Reply

RocketQueen Jul. 2 at 11:28 PM

$OGEN constant rotation PONZI scam pretending to be a legitimate biotech company. They've already started pivoting to the next garbage bin and R/S.

0 · Reply

RocketQueen Jul. 2 at 3:33 PM

$OGEN scam and fraud company headed nowhere fast. Turd polishing with a new logo is not going to help.

0 · Reply

SXCross Jul. 2 at 1:31 PM

$OGEN https://oragenics.com/investor-overview/

0 · Reply

RocketQueen Jul. 2 at 4:11 AM

$OGEN already voting on another 1:50 R/S and the SIGY dilution is going to take the SP down to below compliance by Christmastime. The losses will be exaggerated by the potential failure of the nasal scam too. Janet and the board belong in jail, not running an publicly traded company.

0 · Reply

RocketQueen Jul. 1 at 7:00 PM

$OGEN a new website or logo is just turd polishing. There is ~0% chance the nasal drug will pass phase II clinical trials. Expect and announcement for another 1:50 R/S by next Christmas.

1 · Reply

krim1401 Jul. 1 at 5:35 PM

$OGEN

0 · Reply

NMax Jul. 1 at 2:17 PM

$OGEN Yeah...so anyways... Continuing to accumulate!!! 🤑🤑🤑

0 · Reply

SXCross Jul. 1 at 12:01 PM

$OGEN https://oragenics.com/

1 · Reply

RocketQueen Jul. 1 at 3:09 AM

$OGEN The inventor of the nasal concussion drug is a criminal: https://www.cbsnews.com/news/brett-favre-mississippi-pharmaceutical-company-prevacus-state-welfare-funds/

0 · Reply

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

May 18, 2026, 8:30 AM EDT - 6 weeks ago

ORAGENICS PROVIDES INVESTOR UPDATE

May 7, 2026, 8:30 AM EDT - 2 months ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 5, 2026, 8:30 AM EDT - 2 months ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

2026-04-20T14:01:13.000Z - 2 months ago

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

Apr 13, 2026, 8:30 AM EDT - 2 months ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

2026-03-25T22:35:16.000Z - 3 months ago

Oragenics receives audit opinion with going concern explanation

Mar 25, 2026, 6:30 PM EDT - 3 months ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

2026-03-17T12:49:42.000Z - 3 months ago

Oragenics files annual report on Form 10-K

2026-03-12T12:48:45.000Z - 4 months ago

Oragenics initiates Phase IIa clinical trial site activation

Mar 12, 2026, 8:30 AM EDT - 4 months ago

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

2026-03-11T12:45:33.000Z - 4 months ago

Oragenics explores potential acquisition of additional assets in CNS space

Mar 11, 2026, 8:30 AM EDT - 4 months ago

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

2026-03-10T12:42:00.000Z - 4 months ago

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

Mar 10, 2026, 8:30 AM EDT - 4 months ago

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

2026-02-09T13:46:12.000Z - 5 months ago

Oragenics previews targeted milestones for 2026

Feb 9, 2026, 8:30 AM EST - 5 months ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

2026-02-03T13:40:46.000Z - 5 months ago

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Feb 3, 2026, 8:30 AM EST - 5 months ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

2026-01-22T21:15:38.000Z - 5 months ago

Oragenics files $100M mixed securities shelf

Nov 12, 2025, 8:30 AM EST - 8 months ago

Oragenics Q3 2025 Shareholder Update

2025-10-21T12:15:12.000Z - 9 months ago

Oragenics regains compliance with NYSE

Oct 21, 2025, 8:00 AM EDT - 9 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

2025-10-07T13:20:29.000Z - 9 months ago

Oragenics, Receptor.AI partner to accelerate pipeline development

Oct 7, 2025, 8:30 AM EDT - 9 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

2025-08-11T12:50:19.000Z - 11 months ago

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

Aug 11, 2025, 8:45 AM EDT - 11 months ago

Oragenics Q2 2025 Shareholder Update

2025-07-31T12:52:03.000Z - 1 year ago

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

2025-07-16T12:45:56.000Z - 1 year ago

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

Jul 16, 2025, 8:39 AM EDT - 1 year ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Oragenics Completes Approximately $16.5 Million Offering

2025-07-02T01:00:00.000Z - 1 year ago

Why Is Oragenics Stock (OGEN) Down 55% Today?

2025-07-01T12:50:11.000Z - 1 year ago

Oragenics trading resumes

2025-07-01T12:41:48.000Z - 1 year ago

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

Jul 1, 2025, 8:31 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

2025-07-01T12:05:53.000Z - 1 year ago

Oragenics trading halted, news pending

2025-06-03T13:40:31.000Z - 1 year ago

Oragenics trading resumes

May 13, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 12, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Aug 21, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 16, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 8, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 24, 2024, 6:43 PM EDT - 2 years ago

Oragenics, Inc. Announces Proposed Public Offering

May 22, 2024, 8:00 AM EDT - 2 years ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 17, 2024, 8:00 AM EDT - 2 years ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 4:33 PM EST - 2 years ago

Oragenics Announces Proposed Public Offering

NMax Jul. 4 at 4:28 AM

$OGEN lol... So anyways... continuing to accumulate!!! 🤑🤑🤑

0 · Reply

RocketQueen Jul. 2 at 11:28 PM

$OGEN constant rotation PONZI scam pretending to be a legitimate biotech company. They've already started pivoting to the next garbage bin and R/S.

0 · Reply

RocketQueen Jul. 2 at 3:33 PM

$OGEN scam and fraud company headed nowhere fast. Turd polishing with a new logo is not going to help.

0 · Reply

SXCross Jul. 2 at 1:31 PM

$OGEN https://oragenics.com/investor-overview/

0 · Reply

RocketQueen Jul. 2 at 4:11 AM

0 · Reply

RocketQueen Jul. 1 at 7:00 PM

$OGEN a new website or logo is just turd polishing. There is ~0% chance the nasal drug will pass phase II clinical trials. Expect and announcement for another 1:50 R/S by next Christmas.

1 · Reply

krim1401 Jul. 1 at 5:35 PM

$OGEN

0 · Reply

NMax Jul. 1 at 2:17 PM

$OGEN Yeah...so anyways... Continuing to accumulate!!! 🤑🤑🤑

0 · Reply

SXCross Jul. 1 at 12:01 PM

$OGEN https://oragenics.com/

1 · Reply

RocketQueen Jul. 1 at 3:09 AM

$OGEN The inventor of the nasal concussion drug is a criminal: https://www.cbsnews.com/news/brett-favre-mississippi-pharmaceutical-company-prevacus-state-welfare-funds/

0 · Reply

NMax Jun. 30 at 9:04 PM

$OGEN Yeah...so anyway... Continuing to accumulate!!! 🤑🤑🤑

0 · Reply

SXCross Jun. 30 at 9:42 AM

$OGEN short volume: 752.810 – Quelle: NYSE

1 · Reply

RocketQueen Jun. 30 at 2:06 AM

$OGEN lead product developed by a fraudster. https://www.mississippifreepress.org/accountant-anne-mcgrew-is-first-person-sentenced-in-mississippi-welfare-scandal-but-6-remain-unsentenced/

0 · Reply

NMax Jun. 29 at 9:58 PM

$OGEN Yeah...so anyways.... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Jun. 29 at 4:13 PM

$OGEN this is going to fail phase II, then they do another 1:50 R/S and pivot to another garbage can with the blood laundering scam....

0 · Reply

NMax Jun. 29 at 1:53 PM

$OGEN Anyways! Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Jun. 28 at 2:51 AM

$OGEN another R/S is going to bode well here

0 · Reply

NMax Jun. 26 at 12:59 PM

$OGEN Yeah, anyway... Looking forward to adding more next week!! 🤑🤑🤑

0 · Reply

RocketQueen Jun. 25 at 10:10 PM

$OGEN criminals control the votes here. Management already signaling the failure of phase ıı.

0 · Reply

profitingstocks Jun. 25 at 2:46 PM

$OGEN doesn’t matter what you vote, it never matters. Shitty bio scam stocks like this always get what they want

0 · Reply

NMax Jun. 25 at 2:44 PM

$OGEN Yeah, so, anyway. Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Jun. 25 at 2:41 PM

$OGEN with a vote for another R/S in the pipeline, the stock price is really zero. There is maybe a 2% chance they pass clinical trials.

0 · Reply

Market Cap	2.64M
Revenue (ttm)	0.00
Net Income (ttm)	-9.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	35,500
Avg Vol	49,106
Day's Range	N/A - N/A
Shares Out	4.51M
Stochastic %K	58%
Beta	1.25
Analysts	Strong Buy
Price Target	$2.00